The good news keeps coming! Zilbrysq (zilucoplan) has been listed on the Pharmaceutical Benefits Scheme (PBS) for generalised Myasthenia Gravis (gMG) patients who are AChR antibody positive.*

Zilbrysq (zilucoplan) is a complement inhibitor, and this means that two complement inhibitors are now more widely and more equitably available for our MG patient community in Australia. This means we have access to innovative therapies.

While it is an exciting time, these are new treatments for all of us – doctors and patients alike. Doctors and nurses are in the process of being provided information about the treatments and the process for prescribing them to eligible MG patients.

We understand that patients are also keen to learn about these new treatment options and the MAA will bring information to you as soon as the doctors are ready.

The MAA is your trusted source of information and support. We work in partnership with clinicians, researchers, and industry to ensure you can access accurate and reliable resources. If you haven’t already, check out our website with content that is specific and unique to Australia: https://myastheniaalliance.org.au

The FcRn inhibitor treatments are still progressing through Pharmaceutical Benefits Advisory Committee (PBAC) processes. There is no further information on this treatment group yet.

All the advocacy and stakeholder engagement that has led to this milestone brings us closer to the MAA vision for all MG patients in Australia to have equitable and timely access to the best available treatment that most benefits them.

The MAA thanks the sponsoring company for their work through the PBAC process to offer this therapy for gMG patients via the PBS and for working with us to better understand the new treatments.

A reminder to please talk to your healthcare professional to discuss your treatment options and plan, including any possible side effects or risks.

To read about the other complement inhibitor announcement last month, please see https://myastheniaalliance.org.au/new-targeted-therapy-myasthenia-gravis-pbs/.

If you have any questions or feedback to share with the MAA, please contact us by emailing info@mgaq.org.au or info@myasthenia.org.au, or calling 1800 802 568.

*The MAA and state associations do NOT provide medical advice regarding medications or treatments for individuals. Decisions about whether new treatments will be suitable for you as a patient must be discussed with your doctor or health professional.